financetom
Business
financetom
/
Business
/
National Energy Services Reunited Q2 revenue, profit beat estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
National Energy Services Reunited Q2 revenue, profit beat estimates
Aug 20, 2025 4:10 AM

Overview

* NESR Q2 revenue grows 0.7% YoY, beating analyst expectations

* Adjusted net income for Q2 beats estimates, reaching $20.1 mln

* Adjusted EBITDA rises 13% sequentially, exceeding analyst forecasts

Outlook

* Company anticipates steady growth due to countercyclical investment strategy

* NESR expects continued leadership in Production Services and growth in Drilling

* Company sees diversified country and technology mix driving future revenue

Result Drivers

* DIVERSIFIED MIX - Revenue growth driven by diversified country and technology mix despite global headwinds, per CFO Stefan Angeli

* COST CONTROL - Sequential net income improvement attributed to cost control measures and incremental revenue from existing equipment and personnel

* OPERATIONAL EXECUTION - Strong operational execution reflected in 13% sequential increase in adjusted EBITDA and improved margins

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $327.40 $316.60

Revenue mln mln (3

Analysts

)

Q2 Beat $20.10 $18 mln

Adjusted mln (2

Net Analysts

Income )

Q2 Net $15.20

Income mln

Q2 Beat $70.60 $69.30

Adjusted mln mln (3

EBITDA Analysts

)

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil related services and equipment peer group is "buy"

* Wall Street's median 12-month price target for National Energy Services Reunited Corp ( NESR ) is $12.00, about 39.3% above its August 19 closing price of $7.29

* The stock recently traded at 7 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Equitable Holdings Q3 EPS misses estimates
Equitable Holdings Q3 EPS misses estimates
Nov 4, 2025
Overview * Equitable Holdings ( EQH ) reports Q3 net loss of $1.3 bln due to life reinsurance impact * Adjusted EPS for Q3 misses analyst expectations * Assets under management rose 7% yr/yr to $1.1 trillion Outlook * Equitable Holdings ( EQH ) maintains confidence in achieving 2027 financial targets * Company plans $1.5 bln capital deployment for growth...
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Nov 4, 2025
BOULDER, Colo. & NEW YORK--(BUSINESS WIRE)-- Infleqtion, a global leader in neutral-atom–based quantum technology, and Churchill Capital Corp X ( CCCX ) , a publicly traded special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on October 29, 2025. The submission...
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Nov 4, 2025
Overview * Niagen Bioscience ( NAGE ) Q3 net sales rise 33%, beating analyst expectations * Adjusted EBITDA for Q3 increases 120%, reflecting improved operational performance * Company reaffirms full-year net sales growth outlook of 25% to 30% Outlook * Niagen Bioscience ( NAGE ) reaffirms 2025 net sales growth of 25% to 30% y-o-y * Company expects 2025 gross...
Astronics Q3 sales miss estimates
Astronics Q3 sales miss estimates
Nov 4, 2025
Overview * Astronics ( ATRO ) Q3 sales up 3.8% to $211.4 mln, missing analyst expectations * Company reports Q3 net loss of $11.1 mln due to refinancing-related charges * Adjusted EBITDA for Q3 was $32.7 mln, or 15.5% of sales Outlook * Company expects Q4 revenue between $225 mln and $235 mln * Astronics ( ATRO ) sees 2025...
Copyright 2023-2026 - www.financetom.com All Rights Reserved